| Support (%) | Agreementa |
---|---|---|
Overarching principles | ||
 Patient and physician must share the responsibility of treatment for CSU/CIU | 100 | 4.9 |
 Achieve symptom control and normalize patient’s long-term health-related quality of life | 100 | 4.4 |
 A record of UAS7 must be part of any urticaria treatment to target management plan by measuring disease activity and adjusting therapy accordingly | 100 | 4.6 |
Recommendations | ||
 The primary target for treatment of CSU/CIU should be clinical symptom remission | 100 | 4.4 |
 The patient should be knowledgeable about the treatment target under physician supervision | 100 | 4.8 |
 The use of a validated tool to monitor disease activity | 100 | 4.6 |
 Until the treatment target is reached, drug therapy should be adjusted | 77.8 | 3.7 |
 The treatment target should be sustained throughout the remaining course of the disease management | 100 | 4.6 |